Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation

Corey Cutler, Pratik Multani, David Robbins, Haesook T. Kim, Thuy Le, Jonathan Hoggatt, Louis Pelus, Caroline Desponts, Yi Bin Chen, Betsy Rezner, Philippe Armand, John Koreth, Brett Glotzbecker, Vincent T. Ho, Edwin Alyea, Marlisa Isom, Grace Kao, Myriam Armant, Leslie Silberstein, Peirong Hu & 10 others Robert J. Soiffer, David T. Scadden, Jerome Ritz, Wolfram Goessling, Trista E. North, John Mendlein, Karen Ballen, Leonard I. Zon, Joseph H. Antin, Daniel D. Shoemaker

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells (HSCs) for use in allogeneic transplantation. Key advantages of UCB are rapid availability and less stringent requirements for HLA matching. However, UCB contains an inherently limited HSC count, which is associated with delayed time to engraftment, high graft failure rates, and early mortality. 16,16-Dimethyl prostaglandin E2 (dmPGE2) was previously identified to be a critical regulator of HSC homeostasis, and we hypothesized that brief ex vivo modulation with dmPGE2 could improve patient outcomes by increasing the "effective dose"ofHSCs. Molecular profiling approaches were usedtodetermine the optimalexvivo modulation conditions (temperature, time, concentration, and media) for useinthe clinical setting.A phase1 trial was performedtoevaluate the safety and therapeutic potentialofex vivo modulationofa single UCB unit using dmPGE2 before reduced-intensity, double UCB transplantation. Results from this study demonstrated clear safety with durable, multilineage engraftment of dmPGE2-treated UCB units. We observed encouraging trends in efficacy, with accelerated neutrophil recovery (17.5 vs 21 days, P 5.045), coupled with preferential, long-term engraftment of the dmPGE2-treated UCB unit in 10 of 12 treated participants. This study was registered at www. clinicaltrials.gov as #NCT00890500.

Original languageEnglish
Pages (from-to)3074-3081
Number of pages8
JournalBlood
Volume122
Issue number17
DOIs
StatePublished - Oct 24 2013

Fingerprint

Cord Blood Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
Stem cells
Fetal Blood
Prostaglandins
Blood
Dinoprostone
Hematopoietic Stem Cells
Modulation
Safety
Homologous Transplantation
Grafts
Neutrophils
Homeostasis
Cell Count
Transplantation
Availability
Transplants
Recovery
Temperature

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Cutler, C., Multani, P., Robbins, D., Kim, H. T., Le, T., Hoggatt, J., ... Shoemaker, D. D. (2013). Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation. Blood, 122(17), 3074-3081. https://doi.org/10.1182/blood-2013-05-503177

Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation. / Cutler, Corey; Multani, Pratik; Robbins, David; Kim, Haesook T.; Le, Thuy; Hoggatt, Jonathan; Pelus, Louis; Desponts, Caroline; Chen, Yi Bin; Rezner, Betsy; Armand, Philippe; Koreth, John; Glotzbecker, Brett; Ho, Vincent T.; Alyea, Edwin; Isom, Marlisa; Kao, Grace; Armant, Myriam; Silberstein, Leslie; Hu, Peirong; Soiffer, Robert J.; Scadden, David T.; Ritz, Jerome; Goessling, Wolfram; North, Trista E.; Mendlein, John; Ballen, Karen; Zon, Leonard I.; Antin, Joseph H.; Shoemaker, Daniel D.

In: Blood, Vol. 122, No. 17, 24.10.2013, p. 3074-3081.

Research output: Contribution to journalArticle

Cutler, C, Multani, P, Robbins, D, Kim, HT, Le, T, Hoggatt, J, Pelus, L, Desponts, C, Chen, YB, Rezner, B, Armand, P, Koreth, J, Glotzbecker, B, Ho, VT, Alyea, E, Isom, M, Kao, G, Armant, M, Silberstein, L, Hu, P, Soiffer, RJ, Scadden, DT, Ritz, J, Goessling, W, North, TE, Mendlein, J, Ballen, K, Zon, LI, Antin, JH & Shoemaker, DD 2013, 'Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation', Blood, vol. 122, no. 17, pp. 3074-3081. https://doi.org/10.1182/blood-2013-05-503177
Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J et al. Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013 Oct 24;122(17):3074-3081. https://doi.org/10.1182/blood-2013-05-503177
Cutler, Corey ; Multani, Pratik ; Robbins, David ; Kim, Haesook T. ; Le, Thuy ; Hoggatt, Jonathan ; Pelus, Louis ; Desponts, Caroline ; Chen, Yi Bin ; Rezner, Betsy ; Armand, Philippe ; Koreth, John ; Glotzbecker, Brett ; Ho, Vincent T. ; Alyea, Edwin ; Isom, Marlisa ; Kao, Grace ; Armant, Myriam ; Silberstein, Leslie ; Hu, Peirong ; Soiffer, Robert J. ; Scadden, David T. ; Ritz, Jerome ; Goessling, Wolfram ; North, Trista E. ; Mendlein, John ; Ballen, Karen ; Zon, Leonard I. ; Antin, Joseph H. ; Shoemaker, Daniel D. / Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation. In: Blood. 2013 ; Vol. 122, No. 17. pp. 3074-3081.
@article{5f657fb30f09457e8dcb149b339c3cc1,
title = "Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation",
abstract = "Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells (HSCs) for use in allogeneic transplantation. Key advantages of UCB are rapid availability and less stringent requirements for HLA matching. However, UCB contains an inherently limited HSC count, which is associated with delayed time to engraftment, high graft failure rates, and early mortality. 16,16-Dimethyl prostaglandin E2 (dmPGE2) was previously identified to be a critical regulator of HSC homeostasis, and we hypothesized that brief ex vivo modulation with dmPGE2 could improve patient outcomes by increasing the {"}effective dose{"}ofHSCs. Molecular profiling approaches were usedtodetermine the optimalexvivo modulation conditions (temperature, time, concentration, and media) for useinthe clinical setting.A phase1 trial was performedtoevaluate the safety and therapeutic potentialofex vivo modulationofa single UCB unit using dmPGE2 before reduced-intensity, double UCB transplantation. Results from this study demonstrated clear safety with durable, multilineage engraftment of dmPGE2-treated UCB units. We observed encouraging trends in efficacy, with accelerated neutrophil recovery (17.5 vs 21 days, P 5.045), coupled with preferential, long-term engraftment of the dmPGE2-treated UCB unit in 10 of 12 treated participants. This study was registered at www. clinicaltrials.gov as #NCT00890500.",
author = "Corey Cutler and Pratik Multani and David Robbins and Kim, {Haesook T.} and Thuy Le and Jonathan Hoggatt and Louis Pelus and Caroline Desponts and Chen, {Yi Bin} and Betsy Rezner and Philippe Armand and John Koreth and Brett Glotzbecker and Ho, {Vincent T.} and Edwin Alyea and Marlisa Isom and Grace Kao and Myriam Armant and Leslie Silberstein and Peirong Hu and Soiffer, {Robert J.} and Scadden, {David T.} and Jerome Ritz and Wolfram Goessling and North, {Trista E.} and John Mendlein and Karen Ballen and Zon, {Leonard I.} and Antin, {Joseph H.} and Shoemaker, {Daniel D.}",
year = "2013",
month = "10",
day = "24",
doi = "10.1182/blood-2013-05-503177",
language = "English",
volume = "122",
pages = "3074--3081",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - Prostaglandin-modulated Umbilical cord blood hematopoietic stem cell transplantation

AU - Cutler, Corey

AU - Multani, Pratik

AU - Robbins, David

AU - Kim, Haesook T.

AU - Le, Thuy

AU - Hoggatt, Jonathan

AU - Pelus, Louis

AU - Desponts, Caroline

AU - Chen, Yi Bin

AU - Rezner, Betsy

AU - Armand, Philippe

AU - Koreth, John

AU - Glotzbecker, Brett

AU - Ho, Vincent T.

AU - Alyea, Edwin

AU - Isom, Marlisa

AU - Kao, Grace

AU - Armant, Myriam

AU - Silberstein, Leslie

AU - Hu, Peirong

AU - Soiffer, Robert J.

AU - Scadden, David T.

AU - Ritz, Jerome

AU - Goessling, Wolfram

AU - North, Trista E.

AU - Mendlein, John

AU - Ballen, Karen

AU - Zon, Leonard I.

AU - Antin, Joseph H.

AU - Shoemaker, Daniel D.

PY - 2013/10/24

Y1 - 2013/10/24

N2 - Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells (HSCs) for use in allogeneic transplantation. Key advantages of UCB are rapid availability and less stringent requirements for HLA matching. However, UCB contains an inherently limited HSC count, which is associated with delayed time to engraftment, high graft failure rates, and early mortality. 16,16-Dimethyl prostaglandin E2 (dmPGE2) was previously identified to be a critical regulator of HSC homeostasis, and we hypothesized that brief ex vivo modulation with dmPGE2 could improve patient outcomes by increasing the "effective dose"ofHSCs. Molecular profiling approaches were usedtodetermine the optimalexvivo modulation conditions (temperature, time, concentration, and media) for useinthe clinical setting.A phase1 trial was performedtoevaluate the safety and therapeutic potentialofex vivo modulationofa single UCB unit using dmPGE2 before reduced-intensity, double UCB transplantation. Results from this study demonstrated clear safety with durable, multilineage engraftment of dmPGE2-treated UCB units. We observed encouraging trends in efficacy, with accelerated neutrophil recovery (17.5 vs 21 days, P 5.045), coupled with preferential, long-term engraftment of the dmPGE2-treated UCB unit in 10 of 12 treated participants. This study was registered at www. clinicaltrials.gov as #NCT00890500.

AB - Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells (HSCs) for use in allogeneic transplantation. Key advantages of UCB are rapid availability and less stringent requirements for HLA matching. However, UCB contains an inherently limited HSC count, which is associated with delayed time to engraftment, high graft failure rates, and early mortality. 16,16-Dimethyl prostaglandin E2 (dmPGE2) was previously identified to be a critical regulator of HSC homeostasis, and we hypothesized that brief ex vivo modulation with dmPGE2 could improve patient outcomes by increasing the "effective dose"ofHSCs. Molecular profiling approaches were usedtodetermine the optimalexvivo modulation conditions (temperature, time, concentration, and media) for useinthe clinical setting.A phase1 trial was performedtoevaluate the safety and therapeutic potentialofex vivo modulationofa single UCB unit using dmPGE2 before reduced-intensity, double UCB transplantation. Results from this study demonstrated clear safety with durable, multilineage engraftment of dmPGE2-treated UCB units. We observed encouraging trends in efficacy, with accelerated neutrophil recovery (17.5 vs 21 days, P 5.045), coupled with preferential, long-term engraftment of the dmPGE2-treated UCB unit in 10 of 12 treated participants. This study was registered at www. clinicaltrials.gov as #NCT00890500.

UR - http://www.scopus.com/inward/record.url?scp=84888273208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888273208&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-05-503177

DO - 10.1182/blood-2013-05-503177

M3 - Article

VL - 122

SP - 3074

EP - 3081

JO - Blood

JF - Blood

SN - 0006-4971

IS - 17

ER -